Showing results (1541-1550 of 1,572) with videos related to

Sort By:
Pageof 158
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2020
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100Markus Moehler, Mikhail Dvorkin, Narikazu Boku, et al.
Integrative Organismal Biology (Oxford, England)|October 23, 2023
Understanding Organisms Using Ecological Observatory NetworksB Dantzer, K E Mabry, J R Bernhardt, et al.
Biorxiv : the Preprint Server for Biology|August 15, 2020
Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cellsLanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
Oncotarget|November 27, 2020
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infectionLanlan Zhou, Kelsey Huntington, Shengliang Zhang, et al.
BMC Musculoskeletal Disorders|December 4, 2018
The TeMPO trial (treatment of meniscal tears in osteoarthritis): rationale and design features for a four arm randomized controlled clinical trialJames K Sullivan, James J Irrgang, Elena Losina, et al.
Arthroscopy : the Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association|May 1, 2012
The Development and validation of a self-administered quality-of-life outcome measure for young, active patients with symptomatic hip disease: the International Hip Outcome Tool (iHOT-33)Nicholas G H Mohtadi, Damian R Griffin, M Elizabeth Pedersen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced MalignanciesBenedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.
Cancer|March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinomaLisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.
The Lancet. Oncology|January 17, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trialHoward P Safran, Kathryn Winter, David H Ilson, et al.
American Journal of Clinical Oncology|January 28, 2020
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical TrialRoss A Abrams, Kathryn A Winter, Howard Safran, et al.
Pageof 158